Chandrajit P. Raut, MD
Patients with intermediate- or high-risk gastrointestinal stromal tumors (GIST) were less likely to experience recurrence after 5 years of treatment with imatinib (Gleevec), as determined by results from the phase II PERSIST-5 trial.
However, most AEs were minor. The most common grade 3/4 AEs included abdominal pain (6%), hypophosphatasemia (4%), nausea (3%), and diarrhea (2%).
Raut CP, Espat NJ, Maki RG, et al. PERSIST-5: Five-year extended treatment with adjuvant imatinib for patients with intermediate/high risk primary gastrointestinal stromal tumor (GIST). J Clin Oncol. 35, 2017 (suppl; abstr 11009).
... to read the full story